San Diego’s Sequenom Steps Back Into the Spotlight, Sort Of

(Page 2 of 3)

support Sequenom’s Trisomy 21 test to determine if an unborn infant has Down syndrome. So what happened?

In the financial statement that Sequenom filed yesterday, the company says its independent directors concluded that “we failed to put in place adequate protocols and controls for the conduct of studies in the Trisomy 21 program at our company. Certain of our employees also failed to provide adequate supervision. In the absence of such protocols, controls and supervision, the test data and results in our Trisomy 21 program included inadequately substantiated claims, inconsistencies and errors.”

So what happened as a result?

Sequenom says only that due to “deficiencies in our disclosure controls and procedures” the inadequately substantiated claims, inconsistencies, and errors from its R&D tests “were reported to the public in our press releases and other public statements.” In other words, the only consequence that Sequenom is willing to disclose is that its misleading research data got publicly reported.

One adversary who is agitating for a fuller explanation is David Jaroslawicz, a New York lawyer who represents TrovaGene (formerly known as Xenomics) in a lawsuit filed against Sequenom almost four months ago. TrovaGene says a federal magistrate judge in New York ordered Sequenom to turn over documents sought by Jaroslawicz as part of the case.

TrovaGene is a genetic diagnostics company based in New York and San Diego that had developed rival technology to detect and … Next Page »

Single Page Currently on Page: 1 2 3 previous page

By posting a comment, you agree to our terms and conditions.

Comments are closed.